Publications by authors named "Michelle Ojemuyiwa"

Article Synopsis
  • A patient with advanced neuroendocrine prostate cancer received multiple previous treatments before being part of a Phase II clinical trial.
  • The patient was treated with RRx-001, a dual inhibitor targeting CD-47 and SIRP-α.
  • After undergoing platinum-based chemotherapy, the patient achieved a complete metabolic response, indicating significant improvement in their condition.
View Article and Find Full Text PDF

Poorly differentiated neuroendocrine carcinomas (NECs) are rare tumors that can arise anywhere along the gastrointestinal tract. They often present in advanced stage and portend a poor prognosis when compared to adenocarcinomas of the same stage. Characterization of these tumors is best accomplished with tissue biopsy, as peripheral tumor markers commonly used in NECs are of little utility.

View Article and Find Full Text PDF

Introduction: Prostate cancer (PCa) is the most frequently diagnosed, non-cutaneous malignancy in Western countries. Until recently, few therapeutic options were available for patients with advanced PCa. Although these treatments may delay progression of disease, none are curative.

View Article and Find Full Text PDF